HCWBHIGH SIGNALFINANCIAL10-K

HCWB achieved a dramatic financial turnaround with stockholders' equity swinging from -$6.8M to +$2.8M while reducing net losses by 73%, though accompanied by severe cash depletion and near-complete collapse in gross profit.

The company has successfully addressed its balance sheet insolvency and significantly reduced operating losses, suggesting improved financial discipline or potential restructuring activities. However, the 98.9% decline in gross profit and 58% reduction in cash reserves raises serious questions about revenue sustainability and liquidity runway for this clinical-stage company.

Comparing 2026-03-31 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

HCWB demonstrated a remarkable financial transformation with stockholders' equity improving by $9.6M to positive territory and net losses narrowing dramatically from -$30M to -$8M, while total liabilities decreased substantially by 41.2%. However, these improvements came alongside alarming operational deterioration, including a near-complete collapse in gross profit (98.9% decline) and severe cash depletion with cash equivalents falling 58% to just $2M. The overall picture suggests the company may have undergone significant restructuring or debt conversion that improved its balance sheet position, but with core business performance and liquidity position now representing critical investor concerns.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+140.8%
-$6.8M$2.8M

Equity base grew 140.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
-98.9%
$959K$11K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Net Income
P&L
+73.5%
-$30.0M-$8.0M

Net income grew 73.5% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
-59.9%
$5.7M$2.3M

Current assets declined 59.9% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-58.2%
$4.7M$2.0M

Cash declined 58.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
+55.4%
-$29.5M-$13.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
-41.2%
$37.0M$21.8M

Liabilities reduced 41.2% — deleveraging improves balance sheet strength and financial flexibility.

Interest Expense
P&L
+33.9%
$631K$845K

Interest expense surged 33.9% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
-28.9%
$29.6M$21.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-18.9%
$30.2M$24.5M

Total assets contracted 18.9% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-28
ADDED
HCW BIOLOGICS and TOBI TM are trademarks of HCW Biologics Inc.
( HCW Biologics or the Company ) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation.
We have created novel compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia.
Among other things, we have begun commercialization of certain commercial-ready proprietary compounds for use as reagents in the production of immunotherapeutics for the treatment of infectious diseases and cancer.
We want our products to improve patients healthspan as well as their quality of life, and possibly extend longevity.
+7 more — sign up free →
REMOVED
( HCWB or the Company ) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases.
Our immunotherapeutics represent a new class of drug that we believe has the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation and in doing so, improve patients quality of life and possibly extend longevity.
While chronic inflammation is possible at any age, it is more common as we age.
The induction and retention of low-grade inflammation in an aging human body is mainly the result of the accumulation of non-proliferative but metabolically active senescent cells, which can also be caused by persistent activation of immune cells.
Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to the cause for senescence-associated diseases and conditions that diminish health span, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →